A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
NCT ID: NCT06817356
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
300 participants
INTERVENTIONAL
2025-02-06
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mazdutide
Mazdutide administered subcutaneously (SC).
Mazdutide
Administered SC
Placebo
Placebo administered SC.
Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mazdutide
Administered SC
Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Have initiated psychotherapy, changed the intensity of psychotherapy, or other nondrug therapies (for example, acupuncture or hypnosis) within 8 weeks prior to enrollment.
* Have received any medication for AUD in the last 30 days including but not limited to, disulfiram, acamprosate, naltrexone, gabapentin, baclofen, or topiramate.
21 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
Woodland International Research Group
Little Rock, Arkansas, United States
Woodland Resarch Northwest/ERG
Rogers, Arkansas, United States
Ark Clinical Research - Fountain Valley
Fountain Valley, California, United States
Synergy San Diego
Lemon Grove, California, United States
Headlands Research-Artemis San Diego
San Diego, California, United States
Research Centers of America ( Hollywood )
Hollywood, Florida, United States
K2 Medical Research - Maitland
Maitland, Florida, United States
K2 Medical Research
Maitland, Florida, United States
Clinical Neuroscience Solutions Inc
Orlando, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
K2 Medical Research - Tampa
Tampa, Florida, United States
CenExel iResearch, LLC (CenExel iRA)
Decatur, Georgia, United States
DelRicht Research
Mandeville, Louisiana, United States
Adams Clinical
Watertown, Massachusetts, United States
Vitalix Clinical
Worcester, Massachusetts, United States
Redbird Research LLC
Las Vegas, Nevada, United States
IMA Clinical Research Albuquerque
Albuquerque, New Mexico, United States
Richmond Behavioral Associates
Staten Island, New York, United States
Ichor Research
Syracuse, New York, United States
Davis Clinical
The Bronx, New York, United States
Summit Headlands
Portland, Oregon, United States
Rhode Island Mood & Memory Research Institute
East Providence, Rhode Island, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Clinical Neuroscience Solutions Inc
Memphis, Tennessee, United States
FutureSearch Trials of Dallas
Dallas, Texas, United States
Dallas Clinical Research Center/Pillar Research
Richardson, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Phone: 1-317-615-4559
Email: [email protected]
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I8P-MC-OXAH
Identifier Type: OTHER
Identifier Source: secondary_id
27290
Identifier Type: -
Identifier Source: org_study_id